Recursion Pharmaceuticals, Inc. (RXRX)
| Market Cap | 1.71B |
| Revenue (ttm) | 44.58M |
| Net Income (ttm) | -328.07M |
| Shares Out | 215.83M |
| EPS (ttm) | -1.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,013,562 |
| Open | 7.86 |
| Previous Close | 7.84 |
| Day's Range | 7.68 - 8.06 |
| 52-Week Range | 4.54 - 16.75 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 17.40 (+119.7%) |
| Earnings Date | May 10, 2024 |
About RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; R... [Read more]
Financial Performance
In 2023, RXRX's revenue was $44.58 million, an increase of 11.88% compared to the previous year's $39.84 million. Losses were -$328.07 million, 37.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $17.4, which is an increase of 119.70% from the latest price.
News
Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX
Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent...
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of Directors Dr. Khan,...
Recursion Publishes Annual Environmental, Social and Governance Report
Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact. Provides progress updates i...
Not just Soundhound, these AI stocks are also riding Nvidia wave
Following Nvidia's investment disclosure, SoundHound AI's shares have dramatically increased, tripling in value and boosting its market capitalization to $2.75 billion. The company's success is attrib...
Recursion Announces Plans to Open New Office in London
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the ...
Recursion Hosts Second Annual Rare Disease Day Events for Utah's Rare Disease Community
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, hosted its second annual Rare Di...
Recursion to Participate in Upcoming Investor Conferences
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participatio...
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates a...
Recursion to Host Public L(earnings) Call on February 27
SALT LAKE CITY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide b...
Nvidia discloses investments in smaller AI firms
Nvidia (NVDA) has disclosed investments made in several emerging AI companies, sparking rallies across these stocks. Among the names benefiting include Soundhound (SOUN), Arm (ARM), and Nanox (NNOX).
Shares of Smaller AI Firms Rise After Nvidia Discloses Investments
Shares of smaller artificial intelligence (AI) firms reportedly experienced a rally Thursday (Feb. 15) after Nvidia, the world's leading AI chipmaker, disclosed its stake in them as of Dec. 31. This m...
Altitude Lab Startups Raise Over $120M in Capital
SALT LAKE CITY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altitude Lab today announced that its incubating startups raised over $120M in early-stage funding since commencing operations in 2020. Altitude Lab w...
Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships
Nvidia Corp. NVDA, +4.72% is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships Monday with Amgen Inc. AMGN, +1.26% and Recursion Pharmac...
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
Recursion and NVIDIA will host an invite-only event on Wednesday, January 10, where Recursion will provide live demonstrations of LOWE, its new LLM-based software that can perform complex drug discove...
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets. Screening libraries will leverage Recursion's Mat...
Bayer and Recursion focus research collaboration on Oncology
BERLIN & SALT LAKE CITY--(BUSINESS WIRE)--Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that th...
Bayer and Recursion Focus Research Collaboration on Oncology
Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology ...
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio With additional patient-centric ...
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates a...
Recursion to Participate in Upcoming Investor Conference
SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation...
Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data
Amid fierce debate about prescription-drug prices and countless proposals to rein them in, there has been a point of widespread agreement: Those prices at least partly reflect the vast amount of time,...
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioid...
Recursion Pharmaceuticals stock gets boost after Nvidia results
Shares of Recursion Pharmaceuticals Inc. RXRX, +3.30% jumped more than 4% premarket on Thursday after chip giant Nvidia Corp. NVDA, +3.17% on Wednesday posted blowout quarterly results. Recursion last...
'We look like what the future of all biopharma companies will look like', says Recursion CEO Gibson
Chris Gibson, Recursion CEO, joins 'Closing Bell Overtime' to talk drug development, quarterly earnings, tech integration in pharmaceuticals and more.